Acute exercise decreased plasma insulin and glucose. by Mirian A. Kurauti (3146271)

Relative decreases in VP mean weights using -DDE against TP controls in nine laboratories (Lab) by William Owens (20777)

Density plots of normalised consumer final power (PC) for the six example networks, shown over decreasing ratios of mean consumer to mean resource potential, . by Natalie Davis (8556036)

“…<p>Each plot shows the density for the normalised consumer final power at = 0.75, 0.5, and 0.25, from left to right, as the ratio decreases due to increased resource flow during the simulation. …”

Relative decreases in VP mean weights using VIN against TP controls in eight laboratories (Lab) by William Owens (20777)

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Fig 5 - by Harshita Sharma (4836180)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects: